Description:
 
 
 
 
Background
Cells implanted into the sub‑retinal space have been able to integrate with retinal tissue and result in vision enhancement; one barrier to the success of this approach is loss through efflux and death of the majority (>99%) of implanted cells. 
The precise structural and biochemical cues provided by the native retinal extracellular matrix (ECM) aids in alignment and polarization of seeded cells, enhances differentiation into retinal cell types and facilitates integration with host tissue and vision rescue. 
 
Technology Overview
The novel idea of this invention is the use of native retina extracellular matrix-based materials as biomaterials and cellular delivery vehicles for the treatment of retinal degeneration/disease. Specifically, the inter photoreceptor matrix (IPM), a specialized matrix surrounding the outer segments of photoreceptors and filling the space between the photoreceptors and the retinal pigment epithelium in the eye, is found to be a promising biomaterial base.
 
Benefits
- More precise biomimetic structural and biochemical cues 
- Acts as a cell delivery vehicle
 
Applications
- Retinal regeneration therapies 
- Retinal cell culture
 
Opportunity
- License
- Partnering
- Research collaboration
Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Rebecca Carrier
Keywords:
Health
Materials
Medical
Ocular Disease
Therapeutic